INO Inovio Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: INO

Price (delayed)

$0.9625

Market cap

$250.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$236.12M

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO ...

Highlights
INO's EPS is up by 20% since the previous quarter and by 19% year-on-year
INO's net income is up by 16% since the previous quarter and by 8% year-on-year
INO's quick ratio has dropped by 56% year-on-year and by 11% since the previous quarter
The equity has contracted by 44% YoY and by 17% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.inovio.com
Peers: PFE JNJ ARWR MRK

Key stats

What are the main financial stats of INO
Market
Shares outstanding
260.13M
Market cap
$250.38M
Enterprise value
$236.12M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.08
Price to sales (P/S)
22.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.01
Earnings
Revenue
$10.26M
EBIT
-$278.56M
EBITDA
-$273.07M
Free cash flow
-$217.18M
Per share
EPS
-$1.17
Free cash flow per share
-$0.91
Book value per share
$0.89
Revenue per share
$0.04
TBVPS
$1.41
Balance sheet
Total assets
$348.53M
Total liabilities
$126.17M
Debt
$32.07M
Equity
$222.36M
Working capital
$218.37M
Liquidity
Debt to equity
0.14
Current ratio
3.25
Quick ratio
2.73
Net debt/EBITDA
0.05
Margins
EBITDA margin
-2,660.9%
Gross margin
100%
Net margin
-2,726.7%
Operating margin
-2,607.4%
Efficiency
Return on assets
-68%
Return on equity
-98%
Return on invested capital
-94.8%
Return on capital employed
-110.7%
Return on sales
-2,714.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INO stock price

How has the Inovio Pharmaceuticals stock price performed over time
Intraday
1.73%
1 week
-11.7%
1 month
-24.8%
1 year
-74.4%
YTD
-38.3%
QTD
-38.3%

Financial performance

How have Inovio Pharmaceuticals's revenue and profit performed over time
Revenue
$10.26M
Gross profit
$10.26M
Operating income
-$267.57M
Net income
-$279.82M
Gross margin
100%
Net margin
-2,726.7%
The company's operating margin has surged by 85% YoY and by 10% QoQ
Inovio Pharmaceuticals's net margin has surged by 84% YoY and by 10% QoQ
INO's net income is up by 16% since the previous quarter and by 8% year-on-year
INO's operating income is up by 16% QoQ and by 11% YoY

Growth

What is Inovio Pharmaceuticals's growth rate over time

Valuation

What is Inovio Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.08
P/S
22.38
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
23.01
INO's EPS is up by 20% since the previous quarter and by 19% year-on-year
The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 9.3 and 36% less than its last 4 quarters average of 1.7
The equity has contracted by 44% YoY and by 17% from the previous quarter
The P/S is 92% lower than the 5-year quarterly average of 268.0 and 88% lower than the last 4 quarters average of 189.6
INO's revenue is down by 7% since the previous quarter

Efficiency

How efficient is Inovio Pharmaceuticals business performance
INO's return on sales has surged by 84% year-on-year and by 10% since the previous quarter
INO's ROE has plunged by 57% YoY but it is up by 2.8% from the previous quarter
The company's return on invested capital fell by 47% YoY but it rose by 4.8% QoQ
INO's return on assets is down by 28% year-on-year but it is up by 8% since the previous quarter

Dividends

What is INO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INO.

Financial health

How did Inovio Pharmaceuticals financials performed over time
The total assets is 176% greater than the total liabilities
INO's quick ratio has dropped by 56% year-on-year and by 11% since the previous quarter
INO's current ratio has shrunk by 52% YoY and by 12% QoQ
Inovio Pharmaceuticals's debt is 86% lower than its equity
The debt to equity has soared by 75% YoY and by 17% from the previous quarter
The equity has contracted by 44% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.